The drug NIOH-14, developed by employees of the Vorozhtsov Novosibirsk Institute of Organic Chemistry and the State Scientific Center of Virology and Biotechnology “Vector” , has proven effective in preventing infection with monkeypox (mpox). This is the first chemical drug in Russia for the treatment and emergency prevention of smallpox and other orthopoxvirus diseases in humans.
The vaccine affects orthopoxviruses, prevents the appearance of viral particles outside infected cells and thereby suppresses the development of a viral infection. “[Additional] studies were conducted. The drug showed good results. The studies were conducted by the State Research Center Vector,” said Elena Bagryanskaya, director of the Novosibirsk institute.
